Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | ANPEP | P15144 | 4/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.47 |
| ▸ | CPA3 | P15088 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288170 | 1.00 | SLC7A5 (0.58) | SLC7A5NAALAD2ANPEPENPEPTAAR1 | |
| SCHEMBL29074770 | 1.00 | SLC7A5 (0.58) | SLC7A5NAALAD2ANPEPENPEPTAAR1 | |
| SCHEMBL11473268 | 0.90 | SLC7A5 (0.54) | SLC7A5NAALAD2ANPEPENPEPTAAR1 | |
| SCHEMBL27608497 | 0.88 | SLC7A5 (0.53) | SLC7A5NAALAD2ANPEPENPEPTAAR1 | |
| SCHEMBL13438342 | 0.86 | SLC7A5 (0.53) | SLC7A5TAAR1SLC6A2CA2OPRK1 | |
| SCHEMBL10098450 | 0.86 | SLC7A5 (0.53) | SLC7A5TAAR1SLC6A2CA2OPRK1 | |
| SCHEMBL16103714 | 0.86 | SLC7A5 (0.53) | SLC7A5TAAR1SLC6A2CA2OPRK1 | |
| SCHEMBL288374 | 0.86 | ANPEP (0.49) | SLC7A5NAALAD2ANPEPENPEPS1PR2 | |
| SCHEMBL27999570 | 0.86 | ANPEP (0.49) | SLC7A5NAALAD2ANPEPENPEPS1PR2 | |
| SCHEMBL157500 | 0.85 | CPA3 (0.62) | SLC7A5NAALAD2ANPEPENPEPCPA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697208-B1 | HIGH-FIDELITY LONG-TERM STORAGE OF BIOLOGICAL MATERIAL | CENTRE NAT RECH SCIENT (FR) | 2026-04-22 | — | — | EP | disclosed |
| EP-4687443-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | Genepep (FR) | 2026-02-11 | — | — | EP | disclosed |
| US-20250129082-A1 | N-1 Triazole Substituted Imidazoquinolines, Conjugates Thereof, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-04-24 | — | — | US | disclosed |
| US-12250944-B2 | High-fidelity long-term storage of biological material | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2025-03-18 | — | — | US | disclosed |
| CN-113453724-B | Sulfonylmaleimide-based linkers and corresponding conjugates | 皮埃尔法布雷医药公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-3759107-B1 | SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240350657-A1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | PIERRE FABRE MEDICAMENT (FR) | 2024-10-24 | — | — | US | disclosed |
| EP-4448519-A1 | N-1 TRIAZOLE SUBSTITUTED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | Solventum Intellectual Properties Company (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024208878-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | GENEPEP (FR) | 2024-10-10 | — | — | WO | disclosed |
| EP-3856258-B1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | PF MEDICAMENT (FR) | 2024-07-31 | — | — | EP | disclosed |
| WO-2012085221-A1 | DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE | TFCHEM (FR) | 2012-06-28 | — | — | WO | disclosed |
| EP-2448956-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | Centre National De La Recherche Scientifique CNRS (FR) | 2012-05-09 | — | — | EP | disclosed |
| US-20120108748-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-03 | — | — | US | disclosed |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | UNIVERSITE DE MONTPELLIER I (FR) | 2011-06-23 | — | — | US | disclosed |
| EP-2321277-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | Centre National de la Recherche Scientifique - CNRS (FR) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011000848-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-01-06 | — | — | WO | disclosed |
| EP-2270025-A1 | Solid phase peptide synthesis of peptide alcohols | Centre National pour la Recherche Scientifique (CNRS) (FR) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010023295-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-03-04 | — | — | WO | disclosed |
| US-20080249030-A1 | Age Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-10-09 | — | — | US | disclosed |
| CN-101268093-A | Age inhibitors | PHARMAMENS (FR) | 2008-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108748-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | VIP, ERG28, PSAP | SLC7A5 833/4885NAALAD2 625/4885ANPEP 12/4885 |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | PRRC2C, VIP, PRRC2A | SLC7A5 32/4885NAALAD2 2082/4885ANPEP 253/4885 |
| US-20250129082-A1 | N-1 Triazole Substituted Imidazoquinolines, Conjugates Thereof, and Methods | IFNG, IFNAR1, IL2 | SLC7A5 1589/4885NAALAD2 259/4885ANPEP 1016/4885 |
| US-20240350657-A1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | STS, SULT1E1, CD44 | SLC7A5 543/4885NAALAD2 1129/4885ANPEP 322/4885 |
| US-20080249030-A1 | Age Inhibitors | CFH, XPA, XPNPEP1 | SLC7A5 2318/4885NAALAD2 1241/4885ANPEP 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.